Nephrology

Checking eGFR alone may miss early kidney stress and cardiovascular risk, Payal Kohli, MD, underscores.

Cardiologist Payal Kohli, MD, emphasizes the need to address racial and ethnic disparities in CKD screening, particularly among African Americans, Hispanics, women, and older adults.

Cardiologist Payal Kohli, MD, discusses why relying on eGFR alone may miss early kidney and cardiovascular risk.

Multiple lab options can lead to incorrect UACR testing. Clear ordering practices are essential for actionable results.

A study reveals that using population-based eGFR percentiles can enhance early detection of chronic kidney disease and improve patient outcomes.

Global trends reveal a growing burden of hypertension-related CKD despite advances in blood pressure management.

A recent study reveals declining chronic kidney disease rates in children but rising incidence among young adults, highlighting urgent public health concerns.

A nephrology expert reviews how workflow constraints and care delivery pressures affect adherence to guideline-recommended responses to elevated urine albumin-to-creatinine ratio.

A nephrology expert discusses survey findings that reveal gaps between UACR testing and action in cardiovascular risk assessment for type 2 diabetes.

Your daily dose of the clinical news you may have missed.

Dr Khanna discusses how PCPs can use patient relationships to tailor lifestyle advice and manage obesity-related cardiometabolic disease.

ENDO 2025: The publications reflect growing consensus that integration of endocrine screening into standard clinical workflows is essential for early risk detection and long-term disease prevention.

Baxdrostat met the primary and all secondary endpoints, setting up a first regulatory filing for the selective aldosterone synthase inhibitor, according to AstraZeneca.

Low-dose clorthalidone offers clinicians a new option for initiating treatment that may mitigate well-known metabolic adverse effects.

ACC 2025. Tirzepatide improved HF symptoms and renal function in patients with obesity-related HFpEF, regardless of CKD status, according to new findings from the SUMMIT trial.

Aprocitentan, when added to background therapy of at least 3 antihypertensive agents, led to clinically meaningful and sustained BP reduction in this preplanned subanalysis.

Your daily dose of the clinical news you may have missed.

In November 2024, an FDA advisory committee said the benefits of sotagliflozin do not outweigh the risks in adults with type 1 diabetes and chronic kidney disease.

The data, published in JASN, were presented last week to an FDA advisory committee considering recommending sotagliflozin as an adjunct to insulin in adults with T1D and CKD.

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 11 to 3 against recommending the SGLT1/SLGT2 inhibitor to treat adults with T1D and CKD.

Your daily dose of the clinical news you may have missed.

In a post hoc analysis of the SCORED trial, investigators observed positive renal protection with sotagliflozin across a spectrum of baseline kidney function and glycemic control.

Novo Nordisk plans to file for regulatory approval this year of an expanded label for oral semaglutide, with an indication for reduction of MACE in high-risk adults with T2D.

Lexicon's sotagliflozin is on the October 31 docket for discussion by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee; PDUFA goal date remains set for December 20.

Today, nearly 37 million Americans have chronic kidney disease (CKD), yet only about one percent of those Americans are even aware of their disease. And access to care is under threat.